Results 81 to 90 of about 5,286 (232)

Molecular interactions of bruton's tyrosine kinase [PDF]

, 1997
X-linked agammaglobulinaemia (XLA) is a primary immunodeficiency disorder characterised by a dramatic reduction in the numbers of peripheral B cells and immunoglobulins of all isotypes.
Cory, Giles Oliver Cholmondeley
core  

Bruton's Tyrosine Kinase and Phospholipase Cγ2 Mediate Chemokine-Controlled B Cell Migration and Homing

, 2007
SummaryControl of integrin-mediated adhesion and migration by chemokines plays a critical role in B cell development, differentiation, and function; however, the underlying signaling mechanisms are poorly defined.
de Gorter, David J. J., Rudolf W. Hendriks, Beuling, EA, Marcel Spaargaren, van Gils, JM, van Gils, Janine M., Hendriks, Rudi, Pals, ST, Pals, Steven T., Spaargaren, M, Sabine Middendorp, Kersseboom, Rogier, Middendorp, Sabine, Esther A. Beuling, de Gorter, David J.J., Rogier Kersseboom, Hendriks, Rudolf W., David J.J. de Gorter, de Gorter, DJJ, Spaargaren, Marcel, Steven T. Pals, Beuling, Esther A., Janine M. van Gils   +22 more
core   +1 more source

Bruton’s tyrosine kinase regulates gut immune homeostasis through attenuating Th1 response

Cell Death and Disease, 2021
Inflammatory bowel disease (IBD) is driven by multiple genetic and environmental risk factors. Patients with mutations in Bruton’s tyrosine kinase (BTK) is known to manifest high prevalence of intestinal disorders including IBD. Although BTK mediates the
Di Guan, Zixi Wang, Jianxin Huo, Shengli Xu, Kong-Peng Lam   +4 more
doaj   +1 more source

Src Family Protein Tyrosine Kinases Induce Autoactivation of Bruton's Tyrosine Kinase [PDF]

Molecular and Cellular Biology, 1995
Bruton's tyrosine kinase (Btk) is tyrosine phosphorylated and enzymatically activated following ligation of the B-cell antigen receptor. These events are temporally regulated, and Btk activation follows that of various members of the Src family of protein tyrosine kinases, thus raising the possibility that Src kinases participate in the Btk activation ...
S, Mahajan, J, Fargnoli, A L, Burkhardt, S A, Kut, S J, Saouaf, J B, Bolen   +5 more
openaire   +2 more sources

Response‐adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort

British Journal of Haematology, EarlyView.
Summary Secondary central nervous system lymphoma (SCNSL) remains a rare but challenging manifestation of aggressive lymphomas, with limited prospective data to guide treatment decisions in the modern therapeutic era. We conducted a multicentre retrospective cohort study of 105 consecutively treated adult patients diagnosed with SCNSL between 2016 and ...
Farina Eigendorff, Fabian Görke, Vanja Zeremski, Sophia Wollnitza, Evgenii Shumilov, Georg Lenz, Ellen Obstfelder, Inken Hilgendorf, Vladan Vučinić, Andreas Hochhaus, Ulf Schnetzke   +10 more
wiley   +1 more source

Editorial: Targeting Bruton Tyrosine Kinase

Frontiers in Cell and Developmental Biology, 2022
Brunner, C, Betzler, AC, Brown, JR, Andreotti, AH, Grassilli, E   +4 more
openaire   +5 more sources

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study

British Journal of Haematology, EarlyView.
Real‐world nationwide data in B‐cell malignancies reveal a markedly increased 1‐year incidence of hospitalized atrial fibrillation with ibrutinib compared with second‐generation Bruton's tyrosine kinase inhibitors and venetoclax, arguing for closer cardiac surveillance.
Yoann Zelmat, Loic Ysebaert, Paul Gautier, Agnes Sommet, Margaux Lafaurie, Fabien Despas   +5 more
wiley   +1 more source

Clinical perspective for irreversible tyrosine kinase inhibitors in cancer

, 2012
Irreversible inhibitors provide potent and selective inhibition of tyrosine kinase enzymes. Use of such inhibitors has proved promising in overcoming the tumor resistance encountered with reversible tyrosine kinase inhibitors.
ALFIERI, Roberta, CARMI, Caterina, PETRONINI, Pier Giorgio, MOR, Marco   +3 more
core   +1 more source

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity

Frontiers in Immunology, 2017
Bruton’s tyrosine kinase (BTK) was initially discovered as a critical mediator of B cell receptor signaling in the development and functioning of adaptive immunity.
Alexander N. R. Weber, Zsofia Bittner, Xiao Liu, Truong-Minh Dang, Markus Philipp Radsak, Cornelia Brunner   +5 more
doaj   +1 more source

Scaffold‐free three‐dimensional culture of chronic lymphocytic leukaemia preserves B–T‐cell cross‐talk and enables drug response profiling

British Journal of Haematology, EarlyView.
Summary Chronic lymphocytic leukaemia (CLL) presents a complex biological and clinical landscape, strongly influenced by the tumour microenvironment (TME). To better capture this heterogeneity, we have developed patient‐derived lymphoma spheroids from CLL samples (CLL‐PDLS), which recapitulate the cross‐talk between malignant cells and the autologous ...
Heribert Playa‐Albinyana, Ariadna Giró, Juan A. Piñeyroa, Ferran Araujo‐Ayala, Cèlia Dobaño‐López, Sara Otín‐Sánchez, Elías Campo, Christine Bezombes, Patricia Pérez‐Galán, Dolors Colomer   +9 more
wiley   +1 more source